Physician profile
Ming E Ashworth
NPI 1578578969
$1,228.56
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $86.56 · 2023: $15.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $285.25 | 2019-2020 | |
| Allergan, INC. | $143.00 | 2019 | |
| Amgen INC. | $114.27 | 2019 | |
| Abbvie INC. | $112.39 | 2019-2020 | |
| Insulet Corporation | $97.63 | 2019 | |
| Novo Nordisk INC | $93.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $79.79 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.14 | 2019 | |
| Pfizer INC. | $51.28 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $37.45 | 2019 | |
| Amarin Pharma, INC. | $28.88 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.52 | 2019 | |
| Lilly USA, LLC | $22.95 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.39 | 2019 | |
| Glaxosmithkline, LLC. | $15.18 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $15.13 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Avanir Pharmaceuticals, INC. | $12.63 | 2019 | |
| Aytu Biopharma, INC. | $12.00 | 2019 | |
| Merck Sharp & Dohme LLC | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming Ashworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.